Recruiting

Testing a new medication for early-stage Parkinson's disease

Plain-English translation of NCT07630545 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

This is one of the first times this treatment has been tested in people.

What is this trial?

This is an early-stage study testing a new medication called to see if it could become a disease-modifying treatment for Parkinson's disease. Researchers want to understand how safe the medication is, how well people tolerate it, and how the body processes it. The study involves healthy volunteers and people with mild to moderate Parkinson's disease.

Parkinson's disease is a progressive neurological condition that affects movement and quality of life. Current treatments often manage symptoms but don't slow the disease itself. This trial is exploring whether this medication could work differently — potentially slowing or modifying the disease's progression rather than just relieving symptoms.

Do you qualify?

You likely qualify if…

you are at least 18 years old (some parts open to people 65 and older)
you are generally healthy with no significant medical problems (for healthy volunteer parts), or you have been diagnosed with mild to moderate Parkinson's disease (for the disease-specific part)
you have normal results on blood tests, heart rhythm tests, and vital signs
you test negative for HIV, hepatitis B and C, and drugs of abuse
you are able to attend all study visits and follow-up appointments
you are willing to use effective contraception if you can become pregnant or father a child

You likely don't qualify if…

you have a known allergy or sensitivity to MTX325 or its ingredients
you have had significant abnormal results on recent blood work, heart tests, or imaging
you have a history of severe allergic reactions or certain skin conditions
you are unable to lie still for extended periods or have claustrophobia or needle phobia (for imaging parts)
you have contraindications to MRI or cannot safely have an arterial line placed (for imaging parts)

What participation looks like

Depending on which part of the study you join, you will take the medication or a placebo by mouth in increasing doses, visit the clinic multiple times for blood tests and health monitoring, and possibly undergo imaging scans to see how your body processes the medication. Some participants may visit the clinic as few as 5 times; others may have longer-term follow-up. The entire study could last several months. You will be closely monitored for any side effects or safety concerns throughout.

AI-generated summary from trial data · Jun 15, 2026 · Not medical advice

Trial locations(5 sites)

United Kingdom

Royal Liverpool University Hospital, Liverpool

Parexel, London

Perceptive, London

Simbec-Orion, Merthyr Tydfil

University Hospitals Plymouth NHS Trust, Derriford Hospital, Plymouth